Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis

INTRODUCTION: Biologic agents are used in patients with severe psoriasis who have not adequately responded to existing conventional systemic therapies. However, only a limited number of medical institutions in Japan are approved to use them, and their relatively high cost represents a substantial bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Masayuki, Ozeki, Yasushi, Matsuyama, Fujio, Murata, Tatsunori, Imafuku, Shinichi, Nakamura, Taichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850490/
https://www.ncbi.nlm.nih.gov/pubmed/34951693
http://dx.doi.org/10.1007/s13555-021-00659-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850490/
https://www.ncbi.nlm.nih.gov/pubmed/34951693
http://dx.doi.org/10.1007/s13555-021-00659-w

Ejemplares similares